VCs agree to pump $21M more into developer's nanotech drug

Marinus Pharmaceuticals has found $21 million in Series C financing from the venture outfit Domain Associates and a pharma-focused unit of the Russian investment firm Rusnano. The funding backs further development of the Branford, CT-based developer's nanotechnology-formulated version of the steroid Ganaxolone, which the company licensed from Purdue Pharma, for multiple CNS ailments such as epilepsy, post-traumatic stress disorder, and fragile-X syndrome. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.